Deutsche Telekom supports T-Mobile’s growth plans and rules out share sale in 2026

Timotheus Höttges Chief Executive Officer Deutsche Telekom AG
Timotheus Höttges Chief Executive Officer - Deutsche Telekom AG
0Comments

Deutsche Telekom has expressed support for T-Mobile US Inc.’s growth prospects, following the company’s release of strong financial results for the fourth quarter and full year 2025. The updated outlook from T-Mobile US confirms its continued growth and aligns with the strategic direction outlined at Capital Markets Day 2024.

Currently, Deutsche Telekom holds a majority stake in T-Mobile US, amounting to 52.8 percent of the company’s capital. Since its last reported transaction on October 29, 2025, Deutsche Telekom has not sold any additional shares in T-Mobile US.

The company stated that it does not plan to sell any shares from its T-Mobile US portfolio in 2026. This includes participation in T-Mobile US’s ongoing share buyback program.

Tim Höttges, CEO of Deutsche Telekom, commented: “T-Mobile US has once again delivered strong results in 2025 and is clearly on track to achieve the targets set at Capital Markets Day 2024. As the majority shareholder, we firmly support T-Mobile US’s strategy focused on strong and sustainable earnings growth. We do not plan to sell any T-Mobile US shares from our portfolio in 2026, including within the scope of the ongoing share repurchase program. In addition, we are continuously reviewing opportunities to further increase our stake, provided this makes strategic sense and is financially attractive.”

Deutsche Telekom also noted that this announcement is for informational purposes only and does not constitute an offer or solicitation to purchase securities of either Deutsche Telekom AG or T-Mobile US Inc., particularly in jurisdictions such as the United States where such offers would require registration or an exemption under U.S. law.

The company cautioned that forward-looking statements included in its communication reflect current management views but are subject to risks and uncertainties that could cause actual outcomes to differ materially from those anticipated.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.